Shanghai Xiao Fang Pharmaceutical Co Ltd. Stock Analysis 603207.SS

Shanghai Xiao Fang Pharmaceutical Co., Ltd. engages in research, development, production, and sale of medicines for external use. The company is headquartered in Shanghai, Shanghai and currently employs 404 full-time employees. The company went IPO on 2024-08-26. The firm's products cover digestive, skin and ophthalmic products. Digestive products mainly include enema, glycerin enema, and others. Skin products include calamine lotion, zinc oxide ointment, sulfur ointment, antispasmodic and analgesic tincture, chilblain ointment, compound menthol ointment, urea vitamin E cream, boric acid lotion, benzalkonium bromide tincture, white flower oil, salicylic acid ointment, and others. Ophthalmic products mainly include iodine glycerin, furan nasal drops, ofloxacin ear drops, and others. The firm's products are mainly used to treat constipation, dermatitis and eczema, acne bedsores, traumatic injuries, chilblains, sunburns and burns, tinea capitis, keratin hyperplasia, oral ulcers, gingival swelling and pain, periodontitis, rhinitis and nasal congestion, otitis media and other diseases.